Novo Nordisk Pharmatech A/S — Credit Rating and Financial Key Figures

Novo Nordisk Pharmatech A/S (CVR number: 13246149) is a company from KØGE. The company reported a net sales of 880.4 mDKK in 2023, demonstrating a growth of 47.2 % compared to the previous year. The operating profit percentage was at 10.3 % (EBIT: 90.3 mDKK), while net earnings were 77.2 mDKK. The profitability of the company measured by Return on Assets (ROA) was 8.8 %, which can be considered good and Return on Equity (ROE) was 10.6 %, which can be considered good. The equity ratio, a key indicator for solidity, stood at 60.6 %, a level that can be considered to be good. This shows that a large part of the company's assets are funded by shareholders' equity, reducing financial risk. Novo Nordisk Pharmatech A/S's liquidity measured by quick ratio was 0.6 which is at a low level. Thus, the company may face difficulties in addressing its short-term obligations with its available liquid assets.